Patients who were obese before developing heart failure lived longer than normal weight patients with the same condition according to a new study in the Journal of the American College of Cardiology that examined the “obesity paradox” by following obese and non-obese heart failure patients for more than a decade.

bioresorbable stents

Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely expected to overtake metallic stents in the coming years if the data trend continues. New data from TCT 2014 further reinforces this.

Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. 

Roxwood Medical Inc. announced U.S. Food and Drug Administration (FDA) clearance for the U.S. commercialization of its CenterCross Catheter for use in the coronary and peripheral vasculature.

Innovative Cardiovascular Solutions LLC has completed a Class A Unit financing totaling $5 million to fund its Emblok Embolic Protection Catheter. 

Transcatheter Technologies GmbH announced that it has expanded the Trinity technology platform to include a transfemoral version.

As editor of DAIC, I keep a close watch on trends in cardiovascular technology and try to predict what the next big advancements will be in the coming years. Here are my predictions for technologies to watch in the coming year that have the potential to fundamentally change the practice of cardiology:

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now